Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Advanced Solid Tumor 6Carcinoma, Hepatocellular 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Urinary Bladder Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Sarcoma 1Recurrence 1Mouth Neoplasms 1Melanoma 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

Gemcitabine 79Cisplatin 56pembrolizumab 32Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 13Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × toripalimab × Clear all
NCT04553939 2026-01-02

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Henan Cancer Hospital

Phase 2 Completed
50 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡